David Sinclair

Background

David Sinclair is an Australian-born geneticist and professor in the Department of Genetics at Harvard Medical School, where he co-directs the Paul F. Glenn Center for Biology of Aging Research. Over more than two decades he has become one of the most prominent and polarizing figures in aging biology, known for research on the sirtuin family of enzymes, the metabolite NAD+, the plant compound resveratrol, and a broad hypothesis he calls the information theory of aging. He grew up in Sydney and earned a PhD in molecular genetics from the University of New South Wales in 1995, then moved to MIT for postdoctoral work in the laboratory of Leonard Guarente, where he studied the genetics of aging in yeast and helped identify a role for the sirtuin gene SIR2 in extending lifespan. In 1999 he joined Harvard Medical School and established a lab focused on the molecular controls of aging.

Sirtuins, NAD, and the information theory of aging

Much of Sinclair's early fame rests on sirtuins, a family of enzymes that depend on the coenzyme NAD+ to regulate metabolism, DNA repair, and stress responses. In 2003 he was senior author on a paper reporting that resveratrol, a molecule found in red wine, could activate sirtuins and extend the lifespan of yeast, fueling intense interest in sirtuin-activating compounds and in raising cellular NAD+ with precursors such as NMN and NR. His central hypothesis, the information theory of aging, holds that aging is driven less by damage to the DNA sequence than by the gradual loss of epigenetic information, the marks and packaging that tell cells which genes to switch on. This maps onto the epigenetic alterations counted among the hallmarks of agingArticleHallmarks of AgingA shared framework that organizes aging into interconnected biological processes, giving longevity research a common map of what to measure and target.Read entry →, though Sinclair goes further, proposing that cells retain a youthful backup of their identity that can in principle be restored.

Reprogramming and companies

Building on the discovery by Shinya YamanakaPersonShinya YamanakaJapanese stem-cell scientist who discovered induced pluripotent stem cells and shared the 2012 Nobel Prize, laying the foundation for reprogramming-based rejuvenation.Person → that mature cells can be reset to a younger state, Sinclair's group pursued partial epigenetic reprogramming. In a 2020 Nature paper, his team reported that delivering three reprogramming factors could restore vision in mice with damaged optic nerves and in aged animals, apparently by resetting the epigenetic age of retinal cells, one of the most cited demonstrations that aspects of aging might be reversible. Sinclair has co-founded or advised numerous biotechnology companies, the best known being Sirtris Pharmaceuticals, which he co-founded in 2004 to develop sirtuin-activating drugs and which GlaxoSmithKline acquired in 2008 for about 720 million dollars, though later programs based on its compounds were discontinued. Other ventures include Life Biosciences, MetroBiotech, and OvaScience.

Reception and criticism

In 2019 Sinclair published Lifespan, which argues that aging should be classified and treated as a disease, and he openly discusses a personal regimen that has included metformin, NMN, and resveratrol. His influence on aging biology is substantial, and his lab's reprogramming work is widely respected, yet he has faced pointed criticism. Independent studies questioned whether resveratrol directly activates sirtuins, and some researchers have accused him of overstating the readiness of supplements and interventions. In 2024 he stepped down as president of the Academy for Health and Lifespan Research amid controversy over claims about a longevity supplement for dogs. Reviewers often distinguish between his peer-reviewed science, which is influential, and his public claims about slowing or reversing human aging, which they regard as still unproven.

Related pages

What links here

• Shinya Yamanaka
• Steve Horvath